Streetbeat News

Earnings

HCWB

HCW Biologics (NASDAQ:HCWB) reported Q2 sales of $622.81K, a 37.18% increase from $454.00K in the same period last year. However, the company also reported a net loss of $4.3M, compared to a loss of $3.5M a year ago.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:17 am

ACRV

Acrivon Therapeutics reported Q2 cash, cash equivalents, and marketable securities of $151M. This is expected to fund the company's operations into 2025.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:13 am

ADN

Advent Technologies Hldgs (NASDAQ:ADN) reported Q2 adjusted EPS of $(0.23), missing the estimate of $(0.17) by 35.29%. This is a 9.52% decrease YoY. The company's sales were $1.11M, a 50.02% decrease YoY.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:12 am

ACRV

Acrivon Therapeutics reported Q2 losses of $(0.63) per share, an increase of 80.85% from $(3.29) per share losses in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:12 am

ORGS

Orgenesis (NASDAQ:ORGS) reported Q2 losses of $(0.15) per share, a 31.82% improvement from $(0.22) per share YoY. However, sales decreased by 3.14% to $6.97M from $7.20M YoY.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:10 am

AGLE

Aeglea BioTherapeutics reported Q2 losses of $(2.27) per share, missing the analyst consensus estimate of $(0.15) by 1413.33%. This is a 740.74% decrease from the same period last year. However, the company's quarterly sales of $688.00 thousand beat the analyst consensus estimate of $200.00 thousand by 244.00%, a 10.08% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:08 am

PYXS

Pyxis Oncology reported a Q2 cash balance of $144M, which is expected to support the company's operations into the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:07 am

ACDVF

Air Canada reported Q2 earnings of C$1.85 per share, beating the analyst consensus estimate of C$0.68 by 172.06%. This is a 215.63% increase over losses from the same period last year. The company also reported quarterly sales of C$5.43 billion, beating the analyst consensus estimate of C$5.14 billion by 5.58%, a 36.32% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:06 am

CASI

CASI Pharmaceuticals has reported a sales revenue of $9.8 million for Q2, marking a 15% increase year-over-year and an 18% increase quarter-over-quarter.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:06 am

BFRI

Biofrontera Inc. (NASDAQ:BFRI) has reiterated its expectation for FY23 revenue growth of at least 25% YoY. The company also expects to be cash flow positive within approximately one and a half years.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:06 am